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Abstract
Introduction: Large prospective studies in patients with type 2 diabetes mellitus have demonstrated that metformin
treatment improves cardiovascular prognosis, independent of glycemic control. Administration of metformin potently limits
infarct size in murine models of myocardial infarction. This study examined, for the first time in humans, whether metformin
limits ischemia-reperfusion (IR) injury in vivo using a well-validated forearm model of endothelial IR-injury.
Methods: Twenty-eight healthy volunteers (age 4166 years, 10 male/16 female) were randomized between pretreatment
with metformin (500 mg three times a day for 3 days) or no treatment in a Prospective Randomized Open Blinded Endpoint
study. Brachial artery flow mediated dilation (FMD) was measured before and after 20 minutes of forearm ischemia and
20 minutes of reperfusion. FMD analysis was performed offline by investigators blinded for the treatment arm.
Results: Baseline FMD did not differ between metformin pretreatment and no pretreatment (6.963.6% and 6.163.5%,
respectively, p = 0.27, n = 26). FMD was significantly lower after forearm IR in both treatment arms (4.463.3% and 4.362.8%,
respectively, P,0.001 in both conditions). A linear mixed model analysis revealed that metformin treatment did not prevent
the decrease in FMD by IR.
Conclusion: A 3 day treatment with metformin in healthy, middle-aged subjects does not protect against endothelial IR-
injury, measured with brachial artery FMD after forearm ischemia. Further studies are needed to clarify what mechanism
underlies the cardiovascular benefit of metformin treatment.
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Introduction
Despite optimal reperfusion strategies, morbidity and mortality
remain significant in patients suffering an acute myocardial
infarction. Therefore, much effort is put into developing novel
strategies to limit ischemia-reperfusion (IR) injury.[1] Interestingly,
large observational and intervention studies have shown that
overall cardiovascular mortality is lower in patients with type 2
diabetes mellitus who are treated with metformin, than in patients
treated with alternative glucose-lowering drugs, despite similar
glycemic control.[2–6] This observation suggests that metformin
has direct cardioprotective effects.[7] Indeed, in murine models of
myocardial infarction, performed in diabetic as well as in non-
diabetic animals, administration of metformin limits myocardial
infarct size.[8–11] This cardioprotective effect is mediated by
activation of adenosine monophosphate activated protein kinase
(AMPK) and adenosine receptor stimulation.[9,10] Whether
metformin treatment also directly protects against IR injury in
humans is currently unknown.
Myocardial IR also induces endothelial dysfunction, causing
endothelial swelling and impaired endothelium-dependent relax-
ation, which can further impede proper tissue reperfusion.[12]
Several strategies, including ischemic preconditioning and post-
conditioning have been reported to limit IR-induced endothelial
dysfunction in healthy humans [13,14].
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In this study, we investigate for the first time in humans whether
metformin limits endothelial IR injury in vivo by measuring flow
mediated dilation (FMD) of the brachial artery before and after
prolonged ischemia and reperfusion of the forearm. We test the
hypothesis that short-term pretreatment with metformin limits
endothelial IR injury in humans in vivo.
Methods
Ethics Statement
The protocol is approved by the Institutional Review Board of
the Radboud University Medical Centre, and was performed in
the Radboud University Medical Centre in compliance with the
recommendations of the Declaration of Helsinki. All patients
signed for informed consent before participation. The study is
registered at www.clinicaltrials.gov (NCT01610401). The authors
confirm that all ongoing and related trials for this drug/
intervention are registered. The protocol for this trial and
supporting CONSORT checklist are available as supporting
information; see Checklist S1 and Protocol S1.
Participants
We included 28 healthy, non-smoking adult volunteers in this
study. All subjects were free of cardiovascular disease, diabetes
mellitus, hypertension (systolic blood pressure $140 and/or
diastolic $90 mm Hg) and hypercholesterolemia (random total
cholesterol.6.5 mmol/L). We also excluded professional athletes
and those who were taking concomitant medication. Oral
contraceptive use by female participants was permitted and these
females were asked to continue their contraceptive throughout the
study to maintain stable hormone levels. Females not on oral
contraceptives were measured at identical times in their menstrual
cycle, to exclude any confounding effects of circulating hormones
on endothelial function.[15,16] Two participants withdrew during
the study. Therefore, 26 subjects finished the trial protocol
(Figure 1).
Experimental Design
In a prospective randomized open blinded end-point (PROBE)
study, subjects were allocated to treatment with either metformin
500 mg (Mylan, Bunschoten, The Netherlands) three times a day
for 3 days, to ensure a steady state plasma concentration, or no
pretreatment (figure 1). Simple random allocation was performed
by an independent researcher by dice-throwing for each individual
patient (even number: starting with metformin; uneven number:
starting with no treatment). The last dose of metformin was given
approximately 3 hours before the experiments. Subjects attended
our laboratory twice, separated by at least 14 days to prevent any
cross-over effect of metformin. Brachial artery endothelial function
was measured with flow-mediated dilation (FMD) in the right arm,
before and after 20 minutes of forearm ischemia. Forearm
ischemia was induced by inflating a pneumatic cuff around the
upper arm for 20 minutes and this was followed by 20 minutes of
reperfusion. Patient recruitment was performed between May 15th
2012 and October 4th 2012. The first patient was included on May
15th 2012 and the last visit of the last patient was November 20th
2012.
Measurements
All subjects had to abstain from caffeine consumption and
strenuous exercise for at least 24 hours before the measurement.
Measurements were performed after an overnight fast of at least
6 hours. Before the test, venous blood was taken to assess
metformin and caffeine levels. After removing phospholipids and
proteins with HybridSPE-phospholipids columns (Supelco), the
plasma metformin concentration was determined with LC-MS/
MS, using an Accela U-HPLC (Thermo Fischer Scientific)
coupled to a TSQ Vantage (Thermo Fisher Scientific) triple
quadropole mass spectrometer. The compounds were separated
on a Zorbax HILIC Plus (10062.1 mm, 3.5 mm particle size;
Agilent Technologies). As internal standard we used metformin-
d6 (Toronto Research Chemicals Inc.) The elution gradient was
as follows: 0 min, 100% B; 5 min, 50% B; and 6 min, 100% B.
Solvent A consisted of 2 mM NH4format+0.1% formic acid in
H2O and Solvent B consisted of 2 mM NH4format+0.1% formic
acid in 90% Acetonitril. The column temperature was set at
40uC, and the flow rate was 200 ml/min. The effluent from the
U-HPLC was passed directly into the electrospray ion source.
Positive electrospray ionization was achieved using a nitrogen
sheath gas with ionization voltage at 3500 Volt. The capillary
temperature was set at 290uC. Detection of metformin and the
internal standard was based on isolation of the protonated
molecular ion, [M+H]+ and subsequent MS/MS fragmentations
and a selected reaction monitoring (SRM) were carried out. The
following SRM transitions were used: for metformin m/z
130,1(parent ion) to m/z 60,1 and 71,1 (both product ions) and
for d6-metformin m/z 136,1 (parent ion) to m/z 77,1 (product
ion).
Plasma caffeine concentrations were determined by use of
reversed phase HPLC with UV detection set at 273 nm, as
previously described [17].
Flow Mediated Dilation (FMD). Endothelium-dependent
vasodilation was assessed using FMD according to recent
guidelines.[18] Participants rested in the supine position in a
temperature-controlled room (22uC) for at least 15 minutes to
allow baseline assessment of heart rate and blood flow. The
subjects were tested at the same time of day to prevent diurnal
variation in FMD responses. Mean arterial pressure was deter-
mined using a manual sphygmomanometer placed around the left
arm.
To examine brachial artery FMD, the right arm was extended
and positioned at an angle of ,80u abduction from the torso. A
rapid inflation and deflation pneumatic cuff (D.E. Hokanson,
Bellevue, WA) was placed distal to the olecranon process to
provide an ischemic stimulus distal from the brachial artery. A
10-MHz (T3000, Terason, Aloka, UK) multi-frequency linear
array probe attached to a high-resolution ultrasound machine
was used to perform imaging. The brachial artery was imaged in
the distal third of the upper arm. Ultrasound parameters were set
to optimize longitudinal B-mode images of the lumen/arterial
wall interface. A continuous Doppler velocity assessment was
obtained simultaneously, and data were collected using the lowest
possible insonation angle (always ,60u), which did not vary
during each study. [18] After a resting period of at least
15 minutes, 1 minute of baseline recording of the arterial
diameter and velocity was performed. Subsequently, the occlu-
sion cuff was inflated to 220 mmHg for 5 minutes. The arterial
diameter and velocity recordings were restarted at least
30 seconds before cuff deflation and continued for at least
3 minutes after deflation. Peak arterial diameter and flow, and
the time to reach this peak after cuff deflation, were recorded.
Subsequently, the rapid inflation/deflation pneumatic cuff was
positioned proximally around the upper arm to provide an
occlusion for 20 minutes, so that the brachial artery was within
the ischemic zone and was exposed to IR. The cuff was inflated
for 20 minutes to 220 mmHg, which was followed by 20 minutes
of reperfusion. Finally, the FMD measurement was repeated
20 minutes after reperfusion. All measurements were performed
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by the same, well-experienced sonographer who was blinded for
the treatment allocation.
Brachial Artery Diameter and Blood Flow Analysis
Analysis of the brachial artery diameter was performed by an
investigator who was blinded for the experimental treatment, using
custom-designed edge-detection and wall-tracking software, which
is independent of investigator bias.[19] Baseline data were
calculated across the 1 minute preceding cuff inflation. Following
cuff deflation, peak diameter was automatically detected according
to an algorithm as described in detail elsewhere.[20] Within-
subject reproducibility of the FMD using this semi-automated
software is 6.7–10.5% (coefficient of variation).[21] Post-deflation
shear rate data, derived from velocity and diameter measures, was
used to calculate the area under the shear rate curve (SRAUC).
Statistical Analysis
All data were analyzed using the Statistical Package for the
Social Sciences (SPSS, version 16). Data are presented as
Figure 1. Consort 2012 flow diagram of the study.
doi:10.1371/journal.pone.0096062.g001
Metformin and Ischemia-Reperfusion Injury
PLOS ONE | www.plosone.org 3 April 2014 | Volume 9 | Issue 4 | e96062
mean6SD unless stated otherwise. Baseline parameters between
testing days were compared by paired t-tests.
In a previous study from our laboratory, forearm IR reduced
FMD with 2.6% with a SD of 3.7%. Assuming a correlation
coefficient of 0.7 in our study, given the cross-over design, the
expected SD of the effect of IR on FMD in our study therefore
equals 2.85. With n= 26 subjects, we will be able to detect a
difference of 1.65% with a power of 80% and a type I error
probability of 5%, which is a relevant difference.
In order to evaluate the impact of IR on endothelial function
(measured as FMD), and whether metformin can (partially)
prevent endothelial IR, we employed a linear mixed model
analysis and a two-way repeated measures ANOVA. Furthermore,
according to a recent study by Atkinson et al., inadequate scaling
for FMD would be present if the upper confidence limit of the
regression slope of the relationship between logarithmically
transformed base diameter and peak diameter is less than
one.[22] In such an event, FMD% is not an appropriate measure
to estimate endothelial function. We checked our data for this
phenomenon, and subsequently performed the allometric model-
ling solution proposed by Atkinson et al.[22] Subsequently, the
FMD-values were re-analysed with a linear mixed model analysis
with random factor subject and fixed factors IR (pre versus post),
intervention (metformin versus no treatment), but also whether the
type of intervention was associated with the different impact of IR
on the change in FMD (i.e. interaction IR*intervention). We used
a Kolmogorov-Smirnov test to demonstrate a normal distribution
of our outcome measures (FMD% and allometrically scaled FMD;
P.0.1). The level of statistical significance was set at 0.05.
Results
Baseline characteristics are presented in Table 1. All values were
within the normal range.
The metformin plasma concentration immediately before the
experiment averaged 13576588 ng/ml and were all within the
therapeutic range (494–3237 ng/ml). Median plasma caffeine
concentration was 0.12 (range 0–2.11) mg/dl, with 7 subjects .
1 mg/dl. An overview of the FMD measurements is presented in
table 2. There were no serious adverse events during the trial. At
baseline, we found no differences in brachial artery character-
istics (i.e. baseline diameter, time-to-peak diameter, and shear
rate area-under-the-curve) between both testing days (Table 2).
Baseline FMD% did not differ between metformin pretreatment
and no pretreatment (6.963.6% and 6.163.5%, respectively,
p = 0.27).
The IR protocol induced a significant increase in baseline
brachial artery diameter and a decrease in shear rate stimulus that
was not affected by metformin treatment (Table 2). Both in
absence as well as in presence of metformin, brachial artery
FMD% was significantly lower after forearm IR (4.463.3% and
4.362.7% respectively, p,0.01 in both conditions). A two-way
repeated measures ANOVA revealed that metformin treatment
did not affect the decrease in FMD by IR (Figure 2; p = 0.52).
Subsequent linear mixed model analysis, in which we included
baseline diameter and SRAUC as covariates to correct for the
changes in these parameters after IR, confirmed our primary
finding, in that the decrease in FMD% after IR was not altered by
3-days of metformin intake. A limited number of subjects (n = 7)
had a caffeine concentration .1 mg/ml. Exclusion of these
subjects did not change our conclusion (data not shown).
Discussion
Our current study is the first to investigate whether metformin
limits IR-injury in humans in vivo. Using a well-validated model of
forearm endothelial IR-injury in healthy middle-aged subjects, we
demonstrated that a three day treatment with metformin does not
protect against IR-induced endothelial dysfunction.
Our hypothesis that metformin ameliorates IR-injury is based
on previous epidemiological studies and clinical trials in patient
with diabetes and on preclinical animal studies. First, the United
Kingdom Prospective Diabetes Study (UKPDS) reported that
patients with type 2 diabetes mellitus who were treated with
metformin had a significant lower cardiovascular mortality than
patients treated with alternative glucose-lowering drugs, despite
similar glycemic control.[2] Secondly, recent experimental studies
in mice and rats showed that acute administration of metformin
potently reduced myocardial infarct size. In diabetic and
nondiabetic mice, administration of a single dose of metformin
either before ischemia or at the moment of coronary reperfusion
decreased final infarct size.[8–11] This cardioprotective effect
appeared to be mediated by activation of AMPK and endothelial
Nitric Oxide Synthase (NOS).[9] In addition, Yellon’s group
reported that in diabetic and nondiabetic rat hearts, administra-
tion of metformin reduced infarct size.[8,10,23] In these studies,
the cardioprotective effect was dependent on adenosine receptor
stimulation and activation of important signalling molecules of the
Reperfusion Injury Salvage Kinase (RISK) pathway. Finally, not
only acute single-dose administration of metformin confers
cardioprotection, but also chronic administration of metformin
limits infarct size [23] and beneficially affects postinfarction
myocardial remodelling.[11,24] Based on these studies, we have
recently proposed that metformin treatment is an attractive
strategy to limit IR injury in patients suffering a myocardial
infarction or patients undergoing cardiac surgery [7,25].
To test our hypothesis, we used a well-validated model of IR-
induced endothelial dysfunction in the forearm. Endothelial IR-
injury is relevant for two reasons. First, myocardial ischemia and
reperfusion not only inflicts direct injury to cardiomyocytes, but the
endothelial cells are also highly susceptible to IR-injury.[12]
Indeed, structural endothelial injury occurs during ischemia and
reperfusion, which induces cell swelling and impairment of
endothelial-dependent relaxation, which contributes to the so-
called ‘no-reflow’phenomenon and impedes effective coronary
reperfusion.[26,27] Secondly, endothelial dysfunction is an early
sign of cardiovascular disease and is associated with future
cardiovascular events.[28–31] Importantly, endothelial dysfunction
Table 1. Baseline characteristics.
Variable Value
Age (yrs) 41.366.4
Body weight (kg) 74613
Heigth (cm) 17468
BMI (kg/m2) 24.262.9
Systolic blood pressure (mmHg) 12069
Diastolic blood pressure (mmHg) 7566
Creatinine (mmol/L) 73613





BMI; body mass index, MDRD; modification of diet in renal disease, GFR;
glomerular filtration rate.
doi:10.1371/journal.pone.0096062.t001
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is associated with a worse outcome in several clinical settings.[32–
35] Thus, IR injury to coronary endothelium could contribute to
the increased risk of recurrent atherothrombosis as observed in
patients who present with an acute coronary event.
Several previous studies have reported that twenty minutes of
forearm ischemia impairs subsequent flow mediated dilation
(FMD) of the brachial artery.[13,14] Indeed, this finding was
confirmed in our current study, in which post-IR FMD was 36%
lower than baseline FMD. This observation of a lower FMD, even
after correction for the potential influence of changes in diameter
and the eliciting shear rate stimulus, is in agreement with the
concept that IR causes endothelial dysfunction. Subsequent studies
demonstrated that this IR-induced endothelial dysfunction can be
prevented by ischemic preconditioning, postconditioning, and
remote conditioning.[13,14,36,37] Also, statins significantly re-
duced endothelial IR-injury in this model [38].
In contrast to the preclinical studies, we did not observe any
protective effect of metformin against endothelial IR-injury in our
study. There are several potential explanations for this discrepan-
cy. First, murine models of IR-injury might not reflect the human
situation. In this regard, many interventions that are promising in
animal models do not appear to be effective in clinical trials.[39]
In the field of ischemic stroke, only two of approximately 500
neuroprotective strategies that were beneficial in animal models,
improved outcome in patients.[39] This translational failure can
be due to differences between animal and human (patho)physiol-
ogy, due to methodological flaws in animal studies, or due to
shortcomings of the clinical trial. In the case of metformin-induced
cardioprotection, the evidence is rather strong, with cardioprotec-
tion shown in mice and rats, with or without diabetes, and with
acute as well as chronic administration. The design of our current
study is also robust and uses a well-validated model of endothelial
IR-injury. Although the study was not blinded, we used a PROBE
design, which is a well-accepted design for this kind of studies.
A second explanation could relate to the duration and dose of
metformin pretreatment. Interestingly, in several patient groups,
including patients with type 1 diabetes and patients with polycystic
ovarian syndrome, long-term administration of metformin im-
proves endothelial function, measured with FMD.[40,41] In our
study, however, a three day treatment with metformin did not
improve baseline FMD. Animal studies on the cardioprotective
effect of metformin, however, have demonstrated that either an
acute single dose administration of metformin[9,10] as well as
chronic administration of metformin confer cardioprotection.[23]


























































































































































































































































































































































































































































































































Figure 2. Brachial artery flow mediated dilation (presented as
percentage change from baseline±SE) before (black) and after
(white) 20-minutes for forearm ischemia and 20-minutes
reperfusion preceded by pretreatment with metformin or no
pretreatment.
doi:10.1371/journal.pone.0096062.g002
Metformin and Ischemia-Reperfusion Injury
PLOS ONE | www.plosone.org 5 April 2014 | Volume 9 | Issue 4 | e96062
comparable to or even considerably lower than the dose used to
treat patients with diabetes in clinical practice.[9,10] Based on
these studies, we used a dose of 3dd500 mg, which is a dose often
used to treat patients in clinical practice. Subjects were pretreated
for three days to ensure an effective steady-state plasma
concentration and to enable translation of our results to daily
clinical practice. The last dose of metformin was taken 3 hours
prior to the ischemic episode, which allows for a maximum plasma
concentration of metformin at the moment of forearm ischemia.
Indeed, the circulating plasma concentration of metformin
immediately before the experiment was comparable to the
previous animal studies. In our study,
A third potential explanation for the discrepancy between our
results and results from previous animal studies is that the
mechanism of endothelial IR-injury might differ from IR-injury in
cardiomyocytes. However, most strategies that limit myocardial
infarct size in animal models also conferred protection against
endothelial IR-injury, although some studies could not observe
protection [13,34,36,37].
Fourthly, the findings in the brachial artery may not be
representative for the coronary circulation. However, previous
studies have reported a good correlation between endothelial
responses to flow and vasoactive substances between the brachial
and coronary arteries [42,43].
In conclusion, we can state that short-term metformin
pretreatment does not protect against endothelial dysfunction
induced by ischemia-reperfusion in healthy middle aged subject.
However, whether these results predict the effect of metformin on
myocardial IR-injury and can be extrapolated to subjects with a
history of cardiovascular disease or diabetes mellitus is a matter of
debate. It is important to realize that many comorbidities,
including diabetes mellitus, and comedications can affect the
tolerance against ischemia-reperfusion and the efficacy of cardio-
protective strategies. Therefore, with interest we await further
studies on the effect of metformin on myocardial injury in patients
with a myocardial infarction and patients undergoing coronary
artery bypass grafting (NCT01217307 and NCT01438723
respectively).
Clinical Perspectives
In patients with diabetes, treatment with metformin is associated
with an improved cardiovascular outcome. In contrast to previous
studies in animals, we observed no protective effect of a short term
treatment with metformin on forearm IR-induced endothelial
dysfunction in healthy individuals. Further studies are needed to
clarify what mechanism underlies the cardiovascular benefit of
metformin treatment.
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